Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259542 · ClinicalTrials.gov registry record · Phase 1
Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03259542 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 33 participants.
The verdict
NCT03259542, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A, given with mifepristone 900 mg QD, in healthy male subjects, where all drug administrations are given after a meal.
Interventions
- DRUG Mifepristone 300 MG
- DRUG Itraconazole 100 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-08-09 |
| Est. Completion | 2017-12-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259542
The ClinicalTrials.gov registry entry for NCT03259542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mifepristone 300 MG is the first listed.
NCT03259542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259542 about?
NCT03259542 is a clinical study titled "Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor". This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A, given with mifepristone 900 mg QD, in healthy male subjects, where all drug administrations are given after a meal...
What is the current status of trial NCT03259542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-08-09. Estimated completion is 2017-12-11.
What interventions are being tested in trial NCT03259542?
The interventions under investigation include: Mifepristone 300 MG (DRUG), Itraconazole 100 MG (DRUG).
Who is sponsoring clinical trial NCT03259542?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.